Sodium
2-mercaptoethane-sulfonate (INN: MESNA; Uromitexan' (Asta-Werke AG, FRG, and Boehringer Ingelheim Hospital Division, UK and Eire) is an almost non-toxic thio compound. It is already used in patients who receive oxazaphosphorine cytostatics, such as cyclophosphamide and ifosfamide, to protect the efferent urinary tract, especially the bladder, against the toxic metabolites of these chemotherapeutic agents (Scheef et al., 1979; Brock, 1980) . Until now, protection against the nephrotoxicity of CDDP through MESNA has not been established. CDDP, being a heavy-metal complex, might easily be chelated by sulfhydryl containing compounds, eg by the highly reactive thio-compound MESNA. The only known metabolite of MESNA is MESNA disulfide, which is not capable of reaction (Brock et al., 1982 It was possible to completely protect the kidneys of rats from CDDP-induced damage with sufficient doses of MESNA. (Table I) In addition, two groups of animals, which received 3 times weekly I mg CDDP kg 1 i.p. for 3 weeks, were compared with one another: Maximally tolerated pretreatment hydration with 0.9% NaCl was given to the animals of group 1, while the animals of group 2 received MESNA, dissolved in an equal quantity of water. Animals were killed 12 days after the last application of CDDP. Histological examination of the kidneys of all animals showed severe and intermediate renal changes in 87% of the aniamsl of group 1 and only in 11% of the animals of group 2.
Minimal or no changes were found for 13% in group 1 (no animal without renal changes) and in 89% of the animals of group 2 (70% of which had no renal lesions at all).
In view of the pharmacokinetics of both substances (MESNA and CDDP), MESNA was given orally in these experiments, 400mg kg-body weight, 2 h before each CDDP application, and then every 4h 200mgkg-1 p.o. (4 times daily) up to the 4th day after the last CDDP administration. As a follow-up treatment it was found necessary to maintain protection of the kidneys for an additional 12 days by a single daily dose of 400mg MESNA kg 1 body weight p.o.
To prove that MESNA does not alter the antitumour efficacy of CDDP, we used the SC tumour model 2S 241/38, adenocarcinoma of the stomach. This tumour had been induced by NMethyl-N'-nitro-N-nitroso-guanidine (MNNG) in our laboratory and has now been transplanted s.c. to the 35th passage in BD IX rats. In previous experiments, CDDP proved to be effective against this adenocarcinoma. In 40 BD IX rats this tumour was treated with 3 x 1 mg CDDP kg-1 week -1 for 3 weeks. Twenty animals received additional oral MESNA according to our schedule (see above), the other 20 animals received pretreatment hydration with a balanced electrolyte solution (2 ml 100 gp.o. immediately before each CDDP administration). There was no difference in tumour inhibition between the two groups.
To support these findings, we are testing CDDP and additional nephroprotection by MESNA on leukaemia L1210, which is well known for its sensitivity to CDDP treatment (Rosenberg et al., 1969) . These data will be reported subsequently.
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